H3N2 Infection - Pipeline Review, H1 2014: Market Overview


Published on

H3N2 Infection - Pipeline Review, H1 2014 @ http://www.researchmoz.us/h3n2-infection-pipeline-review-h1-2014-report.html

This report provides comprehensive information on the therapeutic development for H3N2 Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

Published in: Health & Medicine, Business
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

H3N2 Infection - Pipeline Review, H1 2014: Market Overview

  1. 1. H3N2 Infection - Pipeline Review, H1 2014 H3N2 Infection - Pipeline Review, H1 2014 Summary Global Markets Directs, H3N2 Infection - Pipeline Review, H1 2014, provides an overview of the H3N2 Infections therapeutic pipeline. This report provides comprehensive information on the therapeutic development for H3N2 Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for H3N2 Infection and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of H3N2 Infection - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for H3N2 Infection and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the H3N2 Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the H3N2 Infection pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for H3N2 Infection - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding H3N2 Infection pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Table Of Contents table Of Contents 2 list Of Tables 4 list Of Figures 5 introduction 6 global Markets Direct Report Coverage 6 h3n2 Infection Overview 7 therapeutics Development 8 pipeline Products For H3n2 Infection - Overview 8 pipeline Products For H3n2 Infection - Comparative Analysis 9 h3n2 Infection - Therapeutics Under Development By Companies 10 h3n2 Infection - Therapeutics Under Investigation By Universities/institutes 12 h3n2 Infection - Pipeline Products Glance 13 clinical Stage Products 13 early Stage Products 14 H3N2 Infection - Pipeline Review, H1 2014
  2. 2. h3n2 Infection - Products Under Development By Companies 15 h3n2 Infection - Products Under Investigation By Universities/institutes 16 h3n2 Infection - Companies Involved In Therapeutics Development 17 autoimmune Technologies, Llc 17 takeda Pharmaceutical Company Limited 18 nanoviricides, Inc. 19 colby Pharmaceutical Company 20 obio Pharmaceutical Holdings Limited 21 vaxart, Inc. 22 h3n2 Infection - Therapeutics Assessment 23 assessment By Monotherapy Products 23 assessment By Combination Products 24 assessment By Target 25 assessment By Mechanism Of Action 27 assessment By Route Of Administration 29 assessment By Molecule Type 31 drug Profiles 33 bpze1 Vaccine - Drug Profile 33 product Description 33 mechanism Of Action 33 r&d Progress 33 nv-inf-2 - Drug Profile 34 product Description 34 mechanism Of Action 34 r&d Progress 34 tg-21 - Drug Profile 35 product Description 35 mechanism Of Action 35 r&d Progress 35 influenza Vlp Vaccine - Drug Profile 36 product Description 36 mechanism Of Action 36 r&d Progress 36 flufirvitide-3 - Drug Profile 37 product Description 37 mechanism Of Action 37 r&d Progress 37 jvrs-100 + Universal Influenza Vaccine - Drug Profile 38 product Description 38 mechanism Of Action 38 r&d Progress 38 nv-inf-1 - Drug Profile 40 product Description 40 mechanism Of Action 40 r&d Progress 40 id-38 - Drug Profile 42 product Description 42 mechanism Of Action 42 r&d Progress 42 c-05 - Drug Profile 43 product Description 43 mechanism Of Action 43 r&d Progress 43 gamma-flu - Drug Profile 44 product Description 44 mechanism Of Action 44 r&d Progress 44 h3n2 Seasonal Influenza Vaccine - Drug Profile 45 product Description 45 mechanism Of Action 45 r&d Progress 45 h3n2 Infection - Recent Pipeline Updates 46 h3n2 Infection - Dormant Projects 53 h3n2 Infection - Discontinued Products 54 h3n2 Infection - Product Development Milestones 55 featured News & Press Releases 55 dec 21, 2012: Sarepta Therapeutics Enters Into Clinical Trial Agreement With Nih For Further Development Of Influenza Drug Avi-7100 55 oct 09, 2012: Nanoviricides's Oral Flucide Drug Candidate Found To Be Superior To Oseltamivir In Reduction Of Virus Load And Lung Damage Pathology In H3N2 Infection - Pipeline Review, H1 2014
  3. 3. Animal Models With H3n2 Influenza 55 jul 26, 2012: Novartis Begins Shipment Of Fluvirin Seasonal Influenza Vaccine In Us For 2012-2013 Influenza Season 56 appendix 57 methodology 57 coverage 57 secondary Research 57 primary Research 57 expert Panel Validation 57 contact Us 58 disclaimer 58 ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price. Contact: M/s Sheela, 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-997-4948 Email: sales@researchmoz.us Website: http://www.researchmoz.us/ H3N2 Infection - Pipeline Review, H1 2014